Call to Schedule(864) 558-7346
Exact Sciences just rolled out CancerGuard, a multi-cancer early-detection (MCED) blood test that analyzes multiple biomarker classes to flag potential cancer signals—including hard-to-screen types—from a single draw. It’s currently offered in the U.S. as a CLIA lab-developed test (not FDA-approved) and is meant to complement, not replace, guideline screenings; any positive result requires diagnostic follow-up. Coverage is limited for now, with many patients paying out of pocket.
